Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps
- Author
- Philippe Gevaert (UGent) , Doris Lang-Loidolt, Andreas Lackner, Heinz Stammberger, Heribert Staudinger, Thibaut Van Zele (UGent) , Gabriële Holtappels (UGent) , Jan Tavernier (UGent) , Paul Van Cauwenberge (UGent) and Claus Bachert (UGent)
- Organization
- Abstract
- Background: Chronic rhinosinusitis with nasal polyps is characterized by an eosinophilic inflammation and high IL-5 levels. Objectives: Antagonizing the effect of IL-5 is a potential new treatment strategy in patients with nasal polyps. Methods: In a double-blind, placebo-controlled, randomized, 2-center safety and pharmacokinetic study, 24 subjects with bilateral nasal polyps were randomized to receive a single intravenous infusion of reslizumab, a humanized anti-human IL-5 mAb, at 3 mg/kg or 1 mg/kg or placebo. We evaluated the safety and pharmacokinetics of reslizumab, and biologic activity was assessed by means of endoscopic evaluation of polyp size, symptoms, peripheral eosinophil counts, peripheral and local IL-5 levels, eotaxin levels, and eosinophil cationic protein levels. Results: We demonstrated that a single injection of reslizumab up to 3 mg/kg is safe and well tolerated. Blood eosinophil numbers and concentrations of eosinophil cationic protein were reduced up to 8 weeks after treatment in serum and nasal secretions. Individual nasal polyp scores improved only in half of the treated patients for 4 weeks. Responders had increased IL-5 concentrations in nasal secretions at baseline compared with nonresponders, and logistic regression analysis revealed that increased nasal IL-5 levels (> 40 pg/mL) predict the response to anti-IL-5 treatment. Conclusion: A single injection of anti-IL-5 reduces the size of nasal polyps for 4 weeks in half of the patients, and nasal IL-5 levels predict the response to anti-IL-5 treatment. Clinical implications: Intravenous administration of a humanized anti-human IL-5 mAb is safe and reduces the size of nasal polyps in half of the patients.
- Keywords
- HYPERREACTIVITY, anti-IL-5, INDUCED AIRWAY HYPERRESPONSIVENESS, HUMAN INTERLEUKIN-5 RECEPTOR, ANTI-INTERLEUKIN-5 ANTIBODY, DECREASED EXPRESSION, HUMAN EOSINOPHILS, ALPHA EXPRESSION, ASTHMA, MEMBRANE, CYTOKINES, IL-5 receptor alpha, IL-5, eosinphils, nasal polyps, chronic rhinosinusitis
Downloads
-
(...).pdf
- full text
- |
- UGent only
- |
- |
- 729.88 KB
Citation
Please use this url to cite or link to this publication: http://hdl.handle.net/1854/LU-360715
- MLA
- Gevaert, Philippe, et al. “Nasal IL-5 Levels Determine the Response to Anti-IL-5 Treatment in Patients with Nasal Polyps.” JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 118, no. 5, 2006, pp. 1133–41, doi:10.1016/j.jaci.2006.05.031.
- APA
- Gevaert, P., Lang-Loidolt, D., Lackner, A., Stammberger, H., Staudinger, H., Van Zele, T., … Bachert, C. (2006). Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 118(5), 1133–1141. https://doi.org/10.1016/j.jaci.2006.05.031
- Chicago author-date
- Gevaert, Philippe, Doris Lang-Loidolt, Andreas Lackner, Heinz Stammberger, Heribert Staudinger, Thibaut Van Zele, Gabriële Holtappels, Jan Tavernier, Paul Van Cauwenberge, and Claus Bachert. 2006. “Nasal IL-5 Levels Determine the Response to Anti-IL-5 Treatment in Patients with Nasal Polyps.” JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY 118 (5): 1133–41. https://doi.org/10.1016/j.jaci.2006.05.031.
- Chicago author-date (all authors)
- Gevaert, Philippe, Doris Lang-Loidolt, Andreas Lackner, Heinz Stammberger, Heribert Staudinger, Thibaut Van Zele, Gabriële Holtappels, Jan Tavernier, Paul Van Cauwenberge, and Claus Bachert. 2006. “Nasal IL-5 Levels Determine the Response to Anti-IL-5 Treatment in Patients with Nasal Polyps.” JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY 118 (5): 1133–1141. doi:10.1016/j.jaci.2006.05.031.
- Vancouver
- 1.Gevaert P, Lang-Loidolt D, Lackner A, Stammberger H, Staudinger H, Van Zele T, et al. Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. 2006;118(5):1133–41.
- IEEE
- [1]P. Gevaert et al., “Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps,” JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 118, no. 5, pp. 1133–1141, 2006.
@article{360715, abstract = {{Background: Chronic rhinosinusitis with nasal polyps is characterized by an eosinophilic inflammation and high IL-5 levels. Objectives: Antagonizing the effect of IL-5 is a potential new treatment strategy in patients with nasal polyps. Methods: In a double-blind, placebo-controlled, randomized, 2-center safety and pharmacokinetic study, 24 subjects with bilateral nasal polyps were randomized to receive a single intravenous infusion of reslizumab, a humanized anti-human IL-5 mAb, at 3 mg/kg or 1 mg/kg or placebo. We evaluated the safety and pharmacokinetics of reslizumab, and biologic activity was assessed by means of endoscopic evaluation of polyp size, symptoms, peripheral eosinophil counts, peripheral and local IL-5 levels, eotaxin levels, and eosinophil cationic protein levels. Results: We demonstrated that a single injection of reslizumab up to 3 mg/kg is safe and well tolerated. Blood eosinophil numbers and concentrations of eosinophil cationic protein were reduced up to 8 weeks after treatment in serum and nasal secretions. Individual nasal polyp scores improved only in half of the treated patients for 4 weeks. Responders had increased IL-5 concentrations in nasal secretions at baseline compared with nonresponders, and logistic regression analysis revealed that increased nasal IL-5 levels (> 40 pg/mL) predict the response to anti-IL-5 treatment. Conclusion: A single injection of anti-IL-5 reduces the size of nasal polyps for 4 weeks in half of the patients, and nasal IL-5 levels predict the response to anti-IL-5 treatment. Clinical implications: Intravenous administration of a humanized anti-human IL-5 mAb is safe and reduces the size of nasal polyps in half of the patients.}}, author = {{Gevaert, Philippe and Lang-Loidolt, Doris and Lackner, Andreas and Stammberger, Heinz and Staudinger, Heribert and Van Zele, Thibaut and Holtappels, Gabriële and Tavernier, Jan and Van Cauwenberge, Paul and Bachert, Claus}}, issn = {{0091-6749}}, journal = {{JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY}}, keywords = {{HYPERREACTIVITY,anti-IL-5,INDUCED AIRWAY HYPERRESPONSIVENESS,HUMAN INTERLEUKIN-5 RECEPTOR,ANTI-INTERLEUKIN-5 ANTIBODY,DECREASED EXPRESSION,HUMAN EOSINOPHILS,ALPHA EXPRESSION,ASTHMA,MEMBRANE,CYTOKINES,IL-5 receptor alpha,IL-5,eosinphils,nasal polyps,chronic rhinosinusitis}}, language = {{eng}}, number = {{5}}, pages = {{1133--1141}}, title = {{Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps}}, url = {{http://doi.org/10.1016/j.jaci.2006.05.031}}, volume = {{118}}, year = {{2006}}, }
- Altmetric
- View in Altmetric
- Web of Science
- Times cited: